Ocinaplon

Ocinaplon is a drug that was developed by DOV Pharmaceutical and is a member of the pyrazolopyrimidine class. It is an anxiolytic that has similar properties to the benzodiazepine class of medications, but with fewer side effects.

Pharmacology[edit | edit source]

Ocinaplon is a nonselective GABA_A receptor partial agonist, which is the same mechanism of action as benzodiazepines. However, it is more subtype-selective than most benzodiazepines. This means it has the potential to produce less side effects such as sedation, amnesia, or dependence.

Clinical trials[edit | edit source]

In clinical trials, ocinaplon was shown to have anxiolytic properties without producing significant side effects. However, it was withdrawn from a Phase III clinical trial due to concerns about liver safety.

Development and approval[edit | edit source]

The development of ocinaplon was halted in 2005 after the Food and Drug Administration (FDA) requested more information about the drug's safety profile. The FDA was particularly concerned about the potential for liver toxicity, which had been observed in some patients during clinical trials.

See also[edit | edit source]

Ocinaplon Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.